In a clinical study, patients with moderate to severe CF were able to use the PODHALER device1,2
Patient types that were able to generate the inspiratory flow rates and volumes required to receive medication included1:
  • Older patients with significant disease progression and associated decreases in FEV1
  • Younger patients (aged >6 years) with inhaled volumes <1 L
Patients followed the instructions for use. Pediatric patients 6 to 10 years of age with FEV1 <40% predicted were not evaluated1
*This study explored inspiratory variables of 96 patients with CF aged ≥6 years with varying degrees of lung disease while inhaling through mouthpieces with resistance that simulated dry-powder inhaler devices. Enrolled patients were aged 6 to 54 years, with FEV1 19% to 126% predicted.2,3 TOBI PODHALER is indicated for patients with an FEV1 25% to 80% predicted.1
†A flow rate of 40 L/min represents a flow rate more than 2 standard deviations below the mean peak inspiratory flow rates measured for pediatric patients in the study.4
CF: Cystic fibrosis; FEV1: Forced expiratory volume in 1 second.

REFERENCES

  1. TOBI Podhaler; PI; 04/2026.
  2. Tiddens HA, Geller DE, Challoner P, et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J Aerosol Med. 2006;19(4):456-465. doi:10.1089/jam.2006.19.456.
  3. Data on file [TSB-001 The inspiratory volume and flow of cystic fibrosis patients while using a simulated dry powder inhaler]. Mylan Specialty LP; 2003.
  4. Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PULMOSPHERE® Technology. J Aerosol Med Pulm Drug Deliv. 2011;24(4):175-182. doi:10.1089/jamp.2010.0855.